HEADER HYDROLASE/HYDROLASE INHIBITOR 26-NOV-14 4RVI TITLE CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 TITLE 2 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL0519 COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: A, B, C, D; COMPND 4 ENGINEERED: YES; COMPND 5 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HIV-1 PROTEASE-INHIBITOR COMPLEX, GRL0519, G52, PROTEASE INHIBITOR, KEYWDS 2 NON-PEPTIDIC PROTEASE INHIBITOR, HYDROLASE, HYDROLASE-HYDROLASE KEYWDS 3 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.S.YEDIDI,H.GARIMELLA,J.D.KAUFMAN,D.DAS,P.T.WINGFIELD,A.K.GHOSH, AUTHOR 2 H.MITSUYA REVDAT 2 28-FEB-24 4RVI 1 REMARK SEQADV REVDAT 1 04-MAY-16 4RVI 0 JRNL AUTH R.S.YEDIDI,K.MAEDA,M.AOKI,H.GARIMELLA,K.V.RAO,S.AKASAPU, JRNL AUTH 2 D.A.DAVIS,J.D.KAUFMAN,D.DAS,P.T.WINGFIELD,M.AMANO,A.K.GHOSH, JRNL AUTH 3 H.MITSUYA JRNL TITL ENHANCED ANTIVIRAL ACTIVITY BY THE P2-TRIS-TETRAHYDROFURAN JRNL TITL 2 MOIETY OF GRL-0519, A NOVEL NONPEPTIDIC HIV-1 PROTEASE JRNL TITL 3 INHIBITOR (PI), AGAINST MULTI-PI-RESISTANT AND HIGHLY JRNL TITL 4 DARUNAVIR-RESISTANT STRAINS OF HIV-1 JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.99 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.9_1692) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.99 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 32.96 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 0.180 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 27028 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.234 REMARK 3 R VALUE (WORKING SET) : 0.231 REMARK 3 FREE R VALUE : 0.277 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.060 REMARK 3 FREE R VALUE TEST SET COUNT : 1368 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 32.9650 - 4.2846 0.99 2710 143 0.2247 0.2277 REMARK 3 2 4.2846 - 3.4019 1.00 2614 134 0.1992 0.2658 REMARK 3 3 3.4019 - 2.9722 1.00 2580 134 0.2236 0.2733 REMARK 3 4 2.9722 - 2.7006 1.00 2546 154 0.2401 0.2836 REMARK 3 5 2.7006 - 2.5071 1.00 2559 125 0.2364 0.3143 REMARK 3 6 2.5071 - 2.3594 1.00 2537 130 0.2427 0.2678 REMARK 3 7 2.3594 - 2.2412 1.00 2540 125 0.2417 0.2714 REMARK 3 8 2.2412 - 2.1437 1.00 2540 139 0.2461 0.3249 REMARK 3 9 2.1437 - 2.0612 1.00 2532 140 0.2652 0.3205 REMARK 3 10 2.0612 - 1.9900 1.00 2502 144 0.2741 0.3465 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.250 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 32.320 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.009 3268 REMARK 3 ANGLE : 1.247 4444 REMARK 3 CHIRALITY : 0.051 524 REMARK 3 PLANARITY : 0.006 544 REMARK 3 DIHEDRAL : 15.353 1212 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4RVI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-DEC-14. REMARK 100 THE DEPOSITION ID IS D_1000087846. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-MAR-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-F REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RAYONIX MX-225 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28838 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.950 REMARK 200 RESOLUTION RANGE LOW (A) : 33.580 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 7.800 REMARK 200 R MERGE (I) : 0.13400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.51 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.22 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 3M AMMONIUM SULFATE + 0.1 M CITRIC REMARK 280 ACID, PH 5.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 29.48000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 50.37000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 32.36500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 50.37000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.48000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 32.36500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4050 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9620 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -24.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4060 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -23.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 624 O HOH A 628 1.98 REMARK 500 O THR A 4 O HOH A 614 2.13 REMARK 500 OD1 ASP C 35 O HOH C 644 2.15 REMARK 500 O HOH A 672 O HOH A 678 2.17 REMARK 500 O HOH C 626 O HOH C 648 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 87 NE - CZ - NH2 ANGL. DEV. = -3.1 DEGREES REMARK 500 ARG C 87 NE - CZ - NH2 ANGL. DEV. = -3.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO C 79 68.96 -67.32 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G52 A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G52 C 500 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4NJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL008 REMARK 900 RELATED ID: 4NJT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH DARUNAVIR REMARK 900 RELATED ID: 4NJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH TIPRANAVIR REMARK 900 RELATED ID: 4NJV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 REMARK 900 PROTEASE IN COMPLEX WITH RITONAVIR REMARK 900 RELATED ID: 4HLA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH REMARK 900 DARUNAVIR REMARK 900 RELATED ID: 4RVJ RELATED DB: PDB REMARK 900 RELATED ID: 4RVV RELATED DB: PDB REMARK 900 RELATED ID: 4RVX RELATED DB: PDB DBREF 4RVI A 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4RVI B 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4RVI C 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 DBREF 4RVI D 1 99 UNP Q9J006 Q9J006_9HIV1 1 99 SEQADV 4RVI TYR A 42 UNP Q9J006 TRP 42 ENGINEERED MUTATION SEQADV 4RVI CYS A 95 UNP Q9J006 PHE 95 ENGINEERED MUTATION SEQADV 4RVI TYR B 42 UNP Q9J006 TRP 42 ENGINEERED MUTATION SEQADV 4RVI CYS B 95 UNP Q9J006 PHE 95 ENGINEERED MUTATION SEQADV 4RVI TYR C 42 UNP Q9J006 TRP 42 ENGINEERED MUTATION SEQADV 4RVI CYS C 95 UNP Q9J006 PHE 95 ENGINEERED MUTATION SEQADV 4RVI TYR D 42 UNP Q9J006 TRP 42 ENGINEERED MUTATION SEQADV 4RVI CYS D 95 UNP Q9J006 PHE 95 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 A 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 A 99 GLY ARG TYR LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 A 99 GLN LEU GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 B 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 B 99 GLY ARG TYR LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 B 99 GLN LEU GLY CYS THR LEU ASN PHE SEQRES 1 C 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 C 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 C 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 C 99 GLY ARG TYR LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 C 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 C 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 C 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 C 99 GLN LEU GLY CYS THR LEU ASN PHE SEQRES 1 D 99 PRO GLN ILE THR LEU TRP GLN ARG PRO ILE VAL THR ILE SEQRES 2 D 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 D 99 GLY ALA ASP ASP THR VAL LEU GLU ASP MET GLU LEU PRO SEQRES 4 D 99 GLY ARG TYR LYS PRO ARG MET ILE GLY GLY ILE GLY GLY SEQRES 5 D 99 PHE VAL LYS VAL ARG GLN TYR ASP GLN ILE PRO ILE GLU SEQRES 6 D 99 ILE CYS GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 D 99 PRO THR PRO THR ASN ILE ILE GLY ARG ASN LEU MET THR SEQRES 8 D 99 GLN LEU GLY CYS THR LEU ASN PHE HET G52 A 500 84 HET G52 C 500 84 HETNAM G52 (3R,3AS,3BR,6AS,7AS)-OCTAHYDRODIFURO[2,3-B:3',2'- HETNAM 2 G52 D]FURAN-3-YL [(1S,2R)-1-BENZYL-2-HYDROXY-3-{[(4- HETNAM 3 G52 METHOXYPHENYL)SULFONYL](2-METHYLPROPYL) HETNAM 4 G52 AMINO}PROPYL]CARBAMATE FORMUL 5 G52 2(C30 H40 N2 O9 S) FORMUL 7 HOH *213(H2 O) HELIX 1 1 GLY A 86 GLY A 94 1 9 HELIX 2 2 GLY B 86 GLY B 94 1 9 HELIX 3 3 GLY C 86 THR C 91 1 6 HELIX 4 4 GLY D 86 THR D 91 1 6 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N ASN A 98 O THR B 96 SHEET 4 A 4 GLN B 2 THR B 4 -1 O ILE B 3 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O VAL A 56 N ARG A 45 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O VAL A 71 N ILE A 64 SHEET 4 B 8 THR A 31 LEU A 33 1 N LEU A 33 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 ILE A 10 VAL A 15 -1 N VAL A 15 O GLN A 18 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 43 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLY B 52 N GLY B 49 SHEET 3 C 8 HIS B 69 VAL B 77 -1 O HIS B 69 N ILE B 66 SHEET 4 C 8 VAL B 32 LEU B 33 1 N LEU B 33 O LEU B 76 SHEET 5 C 8 ILE B 84 ILE B 85 -1 O ILE B 84 N VAL B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 N LEU B 23 O ILE B 85 SHEET 7 C 8 ILE B 10 VAL B 15 -1 N VAL B 15 O GLN B 18 SHEET 8 C 8 GLY B 52 ILE B 66 -1 O GLU B 65 N LYS B 14 SHEET 1 D 4 GLN C 2 ILE C 3 0 SHEET 2 D 4 THR D 96 ASN D 98 -1 O LEU D 97 N ILE C 3 SHEET 3 D 4 THR C 96 ASN C 98 -1 N THR C 96 O ASN D 98 SHEET 4 D 4 GLN D 2 THR D 4 -1 O ILE D 3 N LEU C 97 SHEET 1 E 8 LYS C 43 ILE C 47 0 SHEET 2 E 8 VAL C 54 ILE C 66 -1 O VAL C 56 N ARG C 45 SHEET 3 E 8 HIS C 69 VAL C 77 -1 O VAL C 71 N ILE C 64 SHEET 4 E 8 VAL C 32 LEU C 33 1 N LEU C 33 O LEU C 76 SHEET 5 E 8 ILE C 84 ILE C 85 -1 O ILE C 84 N VAL C 32 SHEET 6 E 8 GLN C 18 LEU C 24 1 N LEU C 23 O ILE C 85 SHEET 7 E 8 ILE C 10 VAL C 15 -1 N ILE C 13 O LYS C 20 SHEET 8 E 8 VAL C 54 ILE C 66 -1 O GLU C 65 N LYS C 14 SHEET 1 F 8 LYS D 43 GLY D 49 0 SHEET 2 F 8 GLY D 52 ILE D 66 -1 O GLY D 52 N GLY D 49 SHEET 3 F 8 HIS D 69 GLY D 78 -1 O VAL D 71 N ILE D 64 SHEET 4 F 8 THR D 31 GLU D 34 1 N LEU D 33 O LEU D 76 SHEET 5 F 8 ILE D 84 ILE D 85 -1 O ILE D 84 N VAL D 32 SHEET 6 F 8 GLN D 18 LEU D 24 1 N LEU D 23 O ILE D 85 SHEET 7 F 8 ILE D 10 VAL D 15 -1 N ILE D 13 O LYS D 20 SHEET 8 F 8 GLY D 52 ILE D 66 -1 O GLU D 65 N LYS D 14 SITE 1 AC1 27 ARG A 8 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC1 27 ASP A 29 ASP A 30 ILE A 47 GLY A 48 SITE 3 AC1 27 GLY A 49 ILE A 50 PRO A 81 THR A 82 SITE 4 AC1 27 ILE A 84 HOH A 601 ARG B 8 LEU B 23 SITE 5 AC1 27 ASP B 25 GLY B 27 ALA B 28 ASP B 29 SITE 6 AC1 27 ASP B 30 ILE B 47 GLY B 48 GLY B 49 SITE 7 AC1 27 ILE B 50 PRO B 81 ILE B 84 SITE 1 AC2 28 ARG C 8 ASP C 25 GLY C 27 ALA C 28 SITE 2 AC2 28 ASP C 29 ASP C 30 ILE C 47 GLY C 48 SITE 3 AC2 28 GLY C 49 ILE C 50 PRO C 81 THR C 82 SITE 4 AC2 28 ILE C 84 HOH C 604 ARG D 8 LEU D 23 SITE 5 AC2 28 ASP D 25 GLY D 27 ALA D 28 ASP D 29 SITE 6 AC2 28 ASP D 30 ILE D 47 GLY D 48 GLY D 49 SITE 7 AC2 28 ILE D 50 PRO D 81 THR D 82 ILE D 84 CRYST1 58.960 64.730 100.740 90.00 90.00 90.00 P 21 21 21 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016961 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015449 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009927 0.00000